Subscribe: Merck.com - Corporate News
http://www.merck.com/rss/corporate.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
dateline city  english contact  exchange nyse  kenilworth  language english  merck  mrk  nyse  ticker mrk  ticker slug  ticker 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Merck.com - Corporate News

Corporate News





 



Merck Animal Health Completes Acquisition of Vallée S.A.

Wed, 22 Mar 2017 20:05:00 +0000

Dateline City:
MADISON, N.J.

Broadening Our Comprehensive Portfolio of Animal Health Products for Brazilian Market

MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has successfully acquired a controlling interest in Vallée S.A., a leading privately-held producer of animal health products in Brazil.

Language:
English
Contact:

For Merck
Media:
Noreen Verbrugge, 973-937-5450
or
Pamela Eisele, 267-305-3558
or
Investors:
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@MerckAH

read more




FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy

Tue, 14 Mar 2017 21:05:00 +0000

Dateline City:
KENILWORTH, N.J.

Only Anti-PD-1 Therapy Approved for the Treatment of Patients with Difficult-to-Treat cHL Regardless of Prior Stem Cell Transplantation or Use of Brentuximab Vedotin

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, (267) 305-3558
or
Kim Hamilton, (908) 740-1863
or
Investor:
Teri Loxam, (908) 740-1986
or
Amy Klug, (908) 740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer

Tue, 14 Mar 2017 20:43:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for previously treated patients with advanced microsatellite instability-high (MSI-H) cancer. The company recently submitted additional data and analyses to the FDA related to the pending application.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, (267) 305-3558
or
Kim Hamilton, (908) 740-1863
or
Investor:
Teri Loxam, (908) 740-1986
or
Amy Klug, (908) 740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes

Mon, 06 Mar 2017 13:00:00 +0000

Dateline City:
KENILWORTH, N.J. & NEW YORK

Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA ® (sitagliptin) or Metformin

KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S.

Language:
English
Contact:

Merck Media:
Doris Li, (908) 246-5701
or
Merck Investor:
Amy Klug, (908) 740-1898
or
Kristen Drake, (908) 236-4223
or
Pfizer Media:
Steve Danehy, (212) 733-1538
or
Pfizer Investor:
Ryan Crowe, (212) 733-8160

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
Ticker:
FE
Exchange:
NYSE
@Merck

read more




Merck Announces Second-Quarter 2017 Dividend

Tue, 28 Feb 2017 18:47:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.47 per share of the company’s common stock for the second quarter of 2017. Payment will be made on April 7, 2017 to shareholders of record at the close of business on March 15, 2017.

About Merck

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Claire Gillespie, 267-305-0932
or
Investor:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses

Tue, 28 Feb 2017 18:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Findings Reinforce the Need for Greater Discussions Between Health Care Professionals and Patients to Help Them Understand Their Increased Risk For Pneumococcal Pneumonia/Pneumococcal Disease, Flu and Hepatitis B

KENILWORTH, N.J.--(BUSINESS WIRE)--Many adults with diabetes are unaware of their increased risk for certain serious illnesses, including pneumococcal pneumonia/pneumococcal disease, flu and hepatitis B. This is according to a recent national, online consumer awareness survey sponsored by Merck (NYSE:MRK), known as MSD outside the United States and Canada, and the American Diabetes Association, and conducted by Harris Poll.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Skip Irvine, 215-652-6059

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study

Sun, 26 Feb 2017 17:30:00 +0000

Dateline City:
KENILWORTH, N.J.

Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant

Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT), also known as bone marrow transplant (BMT).

Language:
English
Contact:

Merck
Media:
Pam Eisele, 267-305-3558
Robert Consalvo, 908-236-1127
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects

Fri, 24 Feb 2017 21:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Skip Irvine, 267-305-0338
or
Investors:
Amy Klug, 908-740-1898
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions

Thu, 16 Feb 2017 13:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of ILÚM Health Solutions, which provides enterprise-wide disease management tools and services to enable improved outcomes for patients with infectious diseases, such as sepsis and pneumonia, while supporting antimicrobial stewardship initiatives. ILÚM operates independently from Merck’s pharmaceutical and vaccine products businesses as part of Merck’s Healthcare Services & Solutions (HSS) group.

Language:
English
Contact:

Media:
Patrick Witmer, 267-305-4910
or
Investors:
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy

Tue, 14 Feb 2017 22:00:00 +0000

Dateline City:
KENILWORTH, N.J.

APECS Study in People with Prodromal Alzheimer’s Disease to Continue

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with mild-to-moderate Alzheimer’s disease (AD).

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Ian McConnell, 908-740-1921
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial

Tue, 14 Feb 2017 21:05:00 +0000

Dateline City:
KENILWORTH, N.J.

Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-naïve Adults after 48 weeks of Treatment

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI).

Language:
English
Contact:

Merck
Media:
Doris Li, 908-246-5701
Carmen de Gourville, 267-664-0146
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care

Thu, 09 Feb 2017 14:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Alliance Aims to Reduce Disparities in Access to High-Quality Cancer Care

KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation), announced today the selection of the six program sites and National Program Office forming the Alliance to Advance Patient-Centered Cancer Care (the Alliance). With $15 million in funding from the Foundation over five years, the Alliance aims to increase timely access to patient-centered cancer care for vulnerable and underserved populations in the United States.

Language:
English
Contact:

For Merck:
Media:
Lainie Keller, 908-236-5036
or
Jeanine Clemente, 908-236-5059

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




FDA Accepts Two sBLAs for Merck’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings

Fri, 03 Feb 2017 11:45:00 +0000

Dateline City:
KENILWORTH, N.J.

KEYTRUDA Also Receives Breakthrough Therapy Designation for Second-Line Treatment Based on KEYNOTE-045, Which Includes Primary Endpoints of Overall Survival and Progression-Free Survival

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with locally advanced or metastatic urothelial cancer, a type of bladder cancer.

Language:
English
Contact:

For Merck
Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results

Thu, 02 Feb 2017 11:45:00 +0000

Dateline City: KENILWORTH, N.J. Fourth-Quarter 2016 Worldwide Sales Were $10.1 Billion, a Decrease of 1 Percent, Including a 1 Percent Negative Impact from Foreign Exchange; Full-Year 2016 Worldwide Sales Were $39.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange Fourth-Quarter 2016 GAAP EPS Was $0.42; Fourth-Quarter Non-GAAP EPS Was $0.89; Full-Year 2016 GAAP EPS Was $2.04; Full-Year Non-GAAP EPS Was $3.78 2017 Financial Outlook Expects Full-Year 2017 GAAP EPS to be Between $2.47 and $2.62; Expects Non-GAAP EPS to be Between $3.72 and $3.87, Including an Approximately 2 Percent Negative Impact from Foreign Exchange Anticipates Full-Year 2017 Worldwide Sales to be Between $38.6 Billion and $40.1 Billion, Including an Approximately 2 Percent Negative Impact from Foreign Exchange Advanced KEYTRUDA Development Program U.S. Food and Drug Administration (FDA) Approved KEYTRUDA for Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score of 50 Percent or More) Without EGFR or ALK Genomic Tumor Aberrations FDA Granted Priority Review for Three Supplemental Biologics License Applications for KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more[...]



European Commission Approves KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations

Tue, 31 Jan 2017 21:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Approval Based on Data Showing Improved Overall Survival and Progression-Free Survival with KEYTRUDA Compared to Chemotherapy

First Anti-PD-1 Therapy Approved in Europe for Previously Untreated Patients with Metastatic NSCLC

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations.

Language:
English
Contact:

For Merck
Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Pro Football Hall of Famer and Cancer Survivor Jim Kelly Teams Up with Merck and Leading Cancer Organizations to Launch Your Cancer Game Plan

Wed, 25 Jan 2017 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Kelly Provides His “Game Plan” for Navigating Head and Neck Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)--Head and neck cancer survivor and Pro Football Hall of Famer Jim Kelly is sharing his personal experience as part of Your Cancer Game Plan, a new awareness campaign focused on helping people with cancer and their loved ones tackle their emotional, nutritional and communication needs. Kelly, one of the toughest quarterbacks to have played Pro Football, successfully handled the gridiron with his motto ‘Kelly Tough’ – a motto that took on new meaning after he was diagnosed with head and neck cancer.

Language:
English
Contact:

Merck
Media:
Carmen de Gourville, (267) 664-0146
or
Christiana Pascale, (212) 257-6722

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Announces Settlement and License Agreement Resolving KEYTRUDA® (pembrolizumab) Patent Litigation

Fri, 20 Jan 2017 21:01:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA® (pembrolizumab).

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers

Thu, 19 Jan 2017 06:30:00 +0000

Dateline City:
DAVOS, Switzerland

Represents a Critical Step toward Meeting the Sustainable Development Goals for Women, Children and Adolescent Health

DAVOS, Switzerland--(BUSINESS WIRE)--MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., inside the United States and Canada, announced today its $10 million commitment to the Global Financing Facility (GFF) in support of Every Woman Every Child to improve maternal and child health in low- and lower-middle-income countries worldwide through its MSD for Mothers initiative.

Language:
English
Contact:

Media:
MSD for Mothers
Lainie Keller, 908-236-5036
or
Global Financing Facility
Cheryl Toksoz, 202-473-1103
or
Investors:
MSD
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Foundation Grant Expands Project ECHO® in Vietnam and India

Wed, 18 Jan 2017 14:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Project Increases Access to Specialty Care for Complex, Chronic Conditions

KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation) and the Extension for Community Healthcare Outcomes (ECHO) Institute™ at the University of New Mexico Health Sciences Center announced today that the Foundation has provided a grant of $7 million over five years to support the expansion of Project ECHO ® to improve access to specialty care for complex, chronic conditions, such as: hepatitis C, HIV, tuberculosis, and non-communicable diseases, including diabetes and mental health conditions, in underserved communities in India

Language:
English
Contact:

Merck Media Contacts:
Claire Gillespie, 267-305-0932
Jeanine Clemente, 908-236-5059
or
Project ECHO Media Contact:
Andrea Bradford, 505-272-5513

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Tue, 10 Jan 2017 21:06:00 +0000

Dateline City:
KENILWORTH, N.J.

Submission Based on Data from KEYNOTE-021 Trial, Cohort G, Which Enrolled Patients Regardless of PD-L1 Expression

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-236-1108
or
Investor:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)

Mon, 09 Jan 2017 13:00:47 +0000

Dateline City:
WILMINGTON, D.E. & KENILWORTH, N.J.

Additional pivotal studies evaluating Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017

WILMINGTON, D.E. & KENILWORTH, N.J.Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 inhibitor, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Language:
English

read more




Merck to Participate at the 35th Annual J.P. Morgan Healthcare Conference

Fri, 06 Jan 2017 13:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 9, 2017 at 4:00 p.m. PST (7:00 p.m. EST).

Language:
English
Contact:

Media:
Lainie Keller, 908-236-5036
or
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings Conference Call on February 2

Tue, 03 Jan 2017 11:45:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 2. During the call, company executives will provide an overview of Merck’s performance for the quarter and year.

Language:
English
Contact:

Merck
Media:
Lainie Keller, (908) 236-5036
Claire Gillespie, (267) 305-0932
or
Investor:
Teri Loxam, (908) 740-1986
Amy Klug, (908) 740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




KEYTRUDA® (pembrolizumab) Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express High Levels of PD-L1

Mon, 19 Dec 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KEYTRUDA Also Approved for Second-Line Treatment of Patients with Advanced NSCLC Whose Tumors Express PD-L1

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, has been approved in Japan for the treatment of certain patients with PD-L1-positive unresectable advanced/recurrent non-small cell lung cancer (NSCLC) in the first- and second-line treatment settings at a fixed dose of 200 mg every three weeks. MSD will manufacture and market KEYTRUDA in Japan and will promote it with Taiho Pharmaceutical Co., Ltd.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




European Medicines Agency’s CHMP Recommends Merck’s KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor...

Fri, 16 Dec 2016 12:26:00 +0000

Dateline City:
KENILWORTH, N.J.

Opinion Based on Findings from KEYNOTE-024 Trial, Which Showed Superior Overall Survival and Progression Free Survival with KEYTRUDA Compared to Chemotherapy

First Anti-PD-1 Therapy to Receive a CHMP Positive Opinion for Previously Untreated Patients with Metastatic NSCLC

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tu

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more